Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs in ALS
NCT03828123Phase 2Completed
- Sponsor
- Bioinova
- Start
- Jan 2012
- Primary completion
- Aug 2017
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of human autologous MSC 3P in amyotrophic lateral sclerosis (ALS), sponsored by Bioinova. Primary endpoint: Complications related to the medicinal product application at 1 year. Started Jan 2012; status: completed.
02
Drugs
human autologous MSC 3P
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03828123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828123.